Tian X, Chen B, Liu X: Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol 2010, 160:1460–1472.PubMedCrossRef 17. Niu BL, Du HM, Shen HP, Lian ZR, Li JZ, Lai X, et al.: Myeloid

dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. Vaccine 2012, 30:3395–3404.PubMedCrossRef 18. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al.: The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003, 304:661–668.PubMedCrossRef 19. GDC-0980 chemical structure Wright WE, Shay JW, Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability,

linearity and sensitivity. Nucleic Acids Res 1995, 23:3794–3795.PubMedCrossRef 20. Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, et al.: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 2002, 21:3517–3524.PubMedCrossRef 21. Yagoa M, Ohkia R, Hatakeyamaa S, Fujitab T, Ishikawa F: Variant forms of upstream stimulatory Vismodegib datasheet factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett 2002, 520:40–46.CrossRef 22. Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991, 19:2499.PubMedCrossRef 23. Horikawa I, Barrett Cobimetinib mouse JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003, 24:1167–1176.PubMedCrossRef 24. Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G, Wallwiener D: Telomerase activity correlates with tumor aggressiveness

and reflects therapy effect in breast cancer. Int J Cancer 1998, 79:8–12.PubMedCrossRef 25. Timeus F, Crescenzio N, Doria A, Foglia L, Pagliano S, Ricotti E, et al.: In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. Oncol Rep 2012, 27:734–740.PubMed 26. Piccinini M, Rinaldo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, et al.: The HIV protease inhibitors Nelfinavir and Saquinavir, but not a variety of HIV reverse transcriptase inhibitors, affect adversely human proteosome function. Antivir Ther 2005, 10:215–223.PubMed 27. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005, 65:8256–8265.PubMedCrossRef 28. Furuya M, Tsuji N, Kobayashi D, Watanabe AN: Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol 2009, 34:1061–1068.PubMed 29.